Fumarate Hydrate Crystal Form for Selective AKT Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting the PI3K/AKT/mTOR pathway, particularly AKT inhibitors, face challenges in selectivity and efficacy due to side effects from inhibiting upstream or downstream components, and there is a need for more effective and selective AKT inhibitors for cancer treatment.
Innovation Solution
A crystal form of a fumarate hydrate of a dihydropyrido[2,3-d]pyrimidinone derivative with specific X-ray powder diffraction patterns and thermal properties is developed, which serves as a pharmaceutical composition for inhibiting AKT kinase activity, thereby addressing the limitations of existing AKT inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PI3K inhibitors are used to target the pathway, then upstream signal transduction is blocked, but severe side effects occur due to non-selective inhibition
Solution Approach 1:
The patent applies local quality by designing the inhibitor to specifically target the kinase domain of AKT protein while leaving other components of the PI3K/AKT/mTOR pathway unaffected. The molecular structure is optimized to interact with specific amino acid residues in AKT's ATP-binding pocket, ensuring selective inhibition of AKT kinase activity without broadly suppressing upstream or downstream signaling components, thereby reducing side effects while maintaining therapeutic efficacy
2Reliability
If mTOR inhibitors are used to target the pathway, then downstream signaling is blocked, but negative feedback mechanisms reduce drug efficacy
Solution Approach 1:
The patent applies preliminary action by directly inhibiting AKT kinase activity before downstream mTOR signaling can be activated. By blocking AKT at the center of the pathway, the inhibitor prevents the formation of negative feedback loops that would otherwise occur through mTOR-mediated phosphorylation of upstream components, thereby eliminating the adaptive resistance mechanism and maintaining sustained therapeutic efficacy
3Reliability
If existing AKT inhibitors are developed, then AKT kinase activity is inhibited, but selectivity and efficacy remain insufficient for clinical application
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the molecular structure of the inhibitor to achieve optimal binding affinity and selectivity. Specific modifications to the core pyrimidine ring structure, substituent groups, and stereochemical configuration were made to enhance interaction with AKT's ATP-binding site while maintaining appropriate potency levels, resulting in an inhibitor with both high selectivity and sufficient efficacy for clinical development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form effectively inhibits AKT kinase activity, offering improved selectivity and stability, enhancing bioavailability and treatment efficacy for AKT protein kinase-mediated diseases such as breast, prostate, and ovarian cancers.
Implementation Method 1
an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Ka radiation has characteristic peaks at 20 values of 9.28°±0.2° and 3.63°±0.2°
Data Source
AI summary
A salt and crystal form of a dihydropyrido[2,3-d]pyrimidine derivate, and specifically, a crystal form of a fumarate hydrate of compound 1, and a preparation method thereof are provided. In the formula, X is 2.0-3.0. The X-ray powder diffraction pattern expressed in 2θ angles using Cu-Ka radiation has characteristic peaks at 2θ values of 9.28°±0.2° and 3.63°±0.2°. The crystal form has good stability and can better be applied to clinical practice.